Howard  Lee net worth and biography

Howard Lee Biography and Net Worth

Howard Lee, Ph.D. has served as a member of our Board of Directors since August 2007. He previously served as a member of the Board of one of our subsidiaries from 1998 to 2002 and Amphastar’s Board from 2002 to 2004. Dr. Lee is currently the partner at the CID Group, a prominent investment group in the greater China area.  His previous commitment was the Chief Investment Officer at UniMed Venture Management Inc., a biotech venture capital firm. Prior to joining UniMed in July 2009, he was a Managing Director at Silver Biotech Management, Inc. for three years. Dr. Lee served as President and CEO of CDIB Biotech USA Investment Co. Ltd. from October 2000 to June 2006 and as Vice President of China Development Industrial Bank, a prominent investment bank in Taiwan, from October 1995 to June 2006. He carries broad industrial experience from conducting environmental engineering projects in diversified industries since 1993. He also serves as a director for the Development Center of Biotechnology in Taiwan. Dr. Lee earned his B.Sc. at Fu-Jen University (Taiwan), his M.Sc. and Ph.D. degrees in Chemistry from the University of Southern California in Los Angeles in 1990, and completed his postdoctoral research at Loker Hydrocarbon Research Institute of USC.

What is Howard Lee's net worth?

The estimated net worth of Howard Lee is at least $5.59 million as of June 1st, 2023. Mr. Lee owns 142,939 shares of Amphastar Pharmaceuticals stock worth more than $5,594,632 as of December 22nd. This net worth estimate does not reflect any other investments that Mr. Lee may own. Learn More about Howard Lee's net worth.

How do I contact Howard Lee?

The corporate mailing address for Mr. Lee and other Amphastar Pharmaceuticals executives is 11570 SIXTH STREET, RANCHO CUCAMONGA CA, 91730. Amphastar Pharmaceuticals can also be reached via phone at (909) 980-9484 and via email at [email protected]. Learn More on Howard Lee's contact information.

Has Howard Lee been buying or selling shares of Amphastar Pharmaceuticals?

Howard Lee has not been actively trading shares of Amphastar Pharmaceuticals during the past quarter. Most recently, Howard Lee sold 16,679 shares of the business's stock in a transaction on Thursday, June 1st. The shares were sold at an average price of $45.02, for a transaction totalling $750,888.58. Following the completion of the sale, the director now directly owns 142,939 shares of the company's stock, valued at $6,435,113.78. Learn More on Howard Lee's trading history.

Who are Amphastar Pharmaceuticals' active insiders?

Amphastar Pharmaceuticals' insider roster includes Diane Gerst (Director), Richard Koo (Director), Howard Lee (Director), Yakob Liawatidewi (EVP), Mary Luo (COO), Ziping Luo (Chairman), William Peters (CFO), Floyd Petersen (Director), Richard Prins (Director), Michael Zasloff (Director), Jack Zhang (CEO), Yongfeng Zhang (Co-Founder), and Rong Zhou (EVP). Learn More on Amphastar Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Amphastar Pharmaceuticals?

In the last year, insiders at the sold shares 21 times. They sold a total of 363,042 shares worth more than $19,564,696.71. The most recent insider tranaction occured on December, 12th when EVP Rong Zhou sold 7,000 shares worth more than $310,940.00. Insiders at Amphastar Pharmaceuticals own 27.1% of the company. Learn More about insider trades at Amphastar Pharmaceuticals.

Information on this page was last updated on 12/12/2024.

Howard Lee Insider Trading History at Amphastar Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/1/2023Sell16,679$45.02$750,888.58142,939View SEC Filing Icon  
6/6/2022Sell10,291$37.79$388,896.89138,776View SEC Filing Icon  
5/23/2022Sell10,000$34.93$349,300.00138,776View SEC Filing Icon  
5/20/2021Sell10,000$19.74$197,400.00142,914View SEC Filing Icon  
5/20/2020Sell17,782$18.43$327,722.26145,863View SEC Filing Icon  
12/7/2018Sell29,278$21.67$634,454.26133,381View SEC Filing Icon  
11/15/2016Sell37,994$20.65$784,576.10134,527View SEC Filing Icon  
9/1/2016Sell10,381$18.78$194,955.18125View SEC Filing Icon  
12/16/2015Sell38,462$14.34$551,545.08109,901View SEC Filing Icon  
8/25/2014Buy6,000$10.84$65,040.00View SEC Filing Icon  
See Full Table

Howard Lee Buying and Selling Activity at Amphastar Pharmaceuticals

This chart shows Howard Lee's buying and selling at Amphastar Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Amphastar Pharmaceuticals Company Overview

Amphastar Pharmaceuticals logo
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.
Read More

Today's Range

Now: $39.14
Low: $38.96
High: $40.74

50 Day Range

MA: $46.46
Low: $39.14
High: $53.40

2 Week Range

Now: $39.14
Low: $36.56
High: $65.92

Volume

2,483,214 shs

Average Volume

415,267 shs

Market Capitalization

$1.88 billion

P/E Ratio

13.05

Dividend Yield

N/A

Beta

0.78